No disclosed relationships extracted for PHVSyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Nothing on the wire mentions PHVS yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
No earnings record for PHVS on the current feed.
How PHVS has moved on past release days vs its typical ±3.0% day, and how often it closed up. Computed from daily closes — not a forecast.